Komori
Share Issuance and Disposal4519CHUGAI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Details of the Share Acquisition in Connection with the Introduction of a Trust-Type Share-Based Compensation Plan

The details of the scale and timing of the acquisition of the Company's shares under the BIP Trust for directors and the ESOP Trust for employees have been finalized. A total of ¥4.36 billion in trust funds will be contributed under the two plans, and shares will be acquired on the market from 1 May through the end of May 2026.

Worth reading
33Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
4360
¥ million
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Acquisition of the Company's common shares from the market in connection with the trust-based share compensation plan

Conditions on transfer restrictions

Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.

Transfer restriction period
27 April 2026 to the end of May 2030 (trust period)
Categories and Number of Persons Covered
Directors of the Company (excluding directors who do not engage in business execution) and directors of the Company's subsidiaries who meet the beneficiary eligibility requirements; executive officers and employees of the Company, and employees of the Company's subsidiaries, who meet the beneficiary eligibility requirements (the number of eligible participants and shares allocated are Not disclosed)
Intended allottee's holding policy
The disclosure states that the shares acquired by the trusts will be used to provide incentives to eligible participants in the plans; however, the specific holding policy and lock-up arrangements are Not disclosed
Procedures under the Corporate Code of Conduct
Approved at the 115th Annual General Meeting of Shareholders held on 26 March 2026 and at extraordinary general meetings of shareholders of the relevant subsidiaries. The trust administrator is an independent third party with no interest in the Company.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalAcquisition of the Company's common shares from the market in connection with the trust-based share compensation plan
Intended allottee's holding policyThe disclosure states that the shares acquired by the trusts will be used to provide incentives to eligible participants in the plans; however, the specific holding policy and lock-up arrangements are Not disclosed
Transfer restriction period27 April 2026 to the end of May 2030 (trust period)
Categories and Number of Persons CoveredDirectors of the Company (excluding directors who do not engage in business execution) and directors of the Company's subsidiaries who meet the beneficiary eligibility requirements; executive officers and employees of the Company, and employees of the Company's subsidiaries, who meet the beneficiary eligibility requirements (the number of eligible participants and shares allocated are Not disclosed)
Procedures under the Corporate Code of ConductApproved at the 115th Annual General Meeting of Shareholders held on 26 March 2026 and at extraordinary general meetings of shareholders of the relevant subsidiaries. The trust administrator is an independent third party with no interest in the Company.
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide incentives to directors and other officers, employees and others.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Details of the Share Acquisition in Connection with the Introduction of a Trust-Type Share-Based Compensation Plan | CHUGAI PHARMACEUTICAL CO.,LTD. (4519) timely disclosure | Komori